速效救心丸治疗稳定型心绞痛(气滞血瘀证)的疗效与安全性:随机双盲安慰剂对照多中心临床试验方案
本研究为前瞻性、随机、双盲、安慰剂对照、多中心试验,计划纳入324例慢性稳定型心绞痛(气滞血瘀证)患者,在常规治疗基础上分别加用速效救心丸或安慰剂(每次5丸,每日3次)治疗24周。主要结局为入组后4周心绞痛症状改善率和主要不良心血管事件(MACE),旨在为速效救心丸治疗稳定型心绞痛提供高质量临床证据。
要点
- 速效救心丸联合常规治疗稳定型心绞痛,疗程24周,安慰剂对照。
- 主要结局为4周心绞痛症状改善率及主要不良心血管事件(MACE)。
- 试验注册号ChiCTR1900021876,2019年3月14日注册。
核心结论
- 本试验旨在评估速效救心丸治疗稳定型心绞痛(气滞血瘀证)的临床有效性和安全性,为其中西医结合应用提供高质量循证证据。
研究设计与样本
- 前瞻性、随机、双盲、安慰剂对照、多中心临床试验,计划纳入324例慢性稳定型心绞痛(气滞血瘀证)患者。
- 所有参与者均接受慢性稳定型心绞痛常规治疗,随机分为常规治疗加速效救心丸组和常规治疗加安慰剂组。
- 干预为速效救心丸或安慰剂每次5丸口服、每日3次,疗程24周。
关键数值与推荐
- 主要结局为入组后4周心绞痛症状改善率和主要不良心血管事件(MACE)。
- 次要结局包括心绞痛分级(CCS)、中医证候改善、西雅图心绞痛量表评分、急救药物用量及停用率、心电图疗效。
- 整个试验期间监测不良事件。
临床怎么用
- 该方案尚未报告结果,暂不能提供临床用药推荐;结果发表后可为速效救心丸治疗稳定型心绞痛提供循证依据。
局限性
- 本文为试验方案,尚无疗效与安全性结果数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronary heart disease (CHD) has become one of the biggest health problems in the world. Stable angina is a common clinical type of CHD with poor prognosis and high mortality. Although there are various interventions for stable angina, none of them can significantly reduce mortality. Both basic and clinical research have shown that Suxiao Jiuxin Pill (SJP) can relieve the symptoms of angina pectoris and improve the clinical efficacy, but there is a lack of high-quality clinical research to provide research-based evidence. We design a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of SJP for stable angina. METHODS/DESIGN: This is a prospective, randomized, double-blind, placebo-controlled, and multicenter trial. The trial will enroll 324 participants with chronic stable angina (Qi Stagnation and Blood Stasis syndrome). All participants will have received the conventional therapy of chronic stable angina. Participants will be randomized into two groups, conventional therapy plus SJP group and conventional therapy plus placebo group. Eligible participants will receive either SJP or placebo (five pills administered orally, three times daily) in addition to conventional treatment for 24 weeks. The primary outcomes are the symptom improvement rate of angina from baseline to 4 weeks after inclusion and major adverse cardiovascular events (MACE). The secondary outcomes are angina classification (CCS), improvement of traditional Chinese medicine (TCM) syndromes, Seattle Angina Scale score, the dosage of emergency drugs and the stopping rate, and electrocardiogram (EKG) efficacy. Adverse events will be monitored throughout the trial. DISCUSSION: Integrated traditional Chinese and Western Medicine is commonly used for angina in China. This study will evaluate the clinical effectiveness and safety of SJP for angina. The results of the trial will provide high-level clinical research-based evidence for the application of SJP instable angina. TRIAL REGISTRATION: This study protocol was registered on 14 March 2019. The registration number is ChiCTR1900021876 on the Chinese Clinical Trial Registry.
引用
- Ruan X, Li Y, Sun Y, et al. Efficacy and safety of Suxiao Jiuxin Pill in the treatment of stable angina (Qi stagnation and blood stasis syndrome): study protocol of a randomized, double-blind, placebo-controlled, multi-center clinical trial. Trials. 2021. PMID: 34281600. doi:10.1186/s13063-021-05448-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。